Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.
about
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyData management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review.Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control studyNon-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled TrialsDopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia.Current treatment options for hyperprolactinemia.Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.Management of medically refractory prolactinoma.The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.Combining evidence from multiple electronic health care databases: performances of one-stage and two-stage meta-analysis in matched case-control studies.Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies.The safety of treatments for prolactinomas.The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study.Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1.Pharmacological analysis of dopamine modulation in the Drosophila melanogaster larval heart.Risk of heart failure associated with dopamine agonists: a nested case-control study.
P2860
Q26738349-C0DFD4DF-3344-491F-BBD4-CDDAC2A22C37Q30980437-0B4A300C-E86F-4A52-8B7D-F6C3B34C14F8Q36820214-B982D0A9-602B-41EE-917B-A9A36C80308BQ36856977-7858CBAD-4776-4038-A381-3A1F82EC2DA0Q36942889-8479354B-5808-4AEF-A283-74DB3234CDD0Q38112205-63102E14-AA10-4C84-94E0-C08493C73059Q38112589-F33D39C3-F1A6-4704-BCC9-EDA3509B5F5BQ38154516-E4CDAC79-DD83-4068-AE91-F26EFECAB2F3Q38216899-FD6EA9CA-4F1D-40A2-834C-A8E8A84877FEQ38629297-686CFBED-D142-40EB-AE3B-D642F045250CQ38639264-EB1F9A1C-085C-417E-B755-9226F0FB3A62Q38726058-ECF2A0EC-BFB8-46D0-A34F-A95AF995E333Q39595929-1B54C000-3589-4EA5-BBDA-BC1A3354A3DFQ40730569-9A16088C-204A-4CBB-8436-87DADBB60EE0Q42881321-05F1F206-4220-44BC-B6F5-FD198F5E163AQ44784502-6A8D39A9-675F-485C-8736-E5543398CB27
P2860
Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Risk of cardiac valve regurgit ...... ry, nested case-control study.
@en
type
label
Risk of cardiac valve regurgit ...... ry, nested case-control study.
@en
prefLabel
Risk of cardiac valve regurgit ...... ry, nested case-control study.
@en
P2093
P2860
P1433
P1476
Risk of cardiac valve regurgit ...... ry, nested case-control study.
@en
P2093
Cynthia de Luise
Douglas Ross
Eva M van Soest
Giampiero Mazzaglia
Gianluca Trifirò
Guy Brusselle
Guy van Camp
Jeanne P Dieleman
Katia Verhamme
M Mostafa Mokhles
P2860
P304
P356
10.2165/11594940-000000000-00000
P577
2012-02-01T00:00:00Z
P5875
P6179
1017287253